Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

Table 4 Estimated probabilities, means and standard deviations of the change in number of letters from baseline at month 1 for dexamethasone and sham for BRVO and CRVO for ranges compatible with GENEVA

	BRVO			CRVO
Improvement or worsening at month 1	Dexamethasone	Sham	Relative risk*	Dexamethasone	Sham	Relative risk*
Gain ≥15 letters	0.231	0.086	2.70	0.213	0.068	3.13
Gain ≥5 and <15 letters	0.488	0.373	1.31	0.412	0.245	1.68
Loss <5 letters and gain <5 letters	0.257	0.440	0.58	0.301	0.482	0.62
Loss ≥5 letters and <15 letters	0.024	0.095	0.25	0.037	0.135	0.27
Loss ≥15 letters	0.000	0.006	0	0.037	0.068	0.54
Gain ≥10 letters	0.434	0.202	2.15	0.456	0.122	3.74
Mean improvement (letters)	8.498	3.799		7.200	0.400
SD improvement^§	7.917	7.916		10.721	10.721

*Ratio of treatment (dexamethasone) probability to control (Sham) probability. ^§Estimated from reported limits on change BCVA.

ISSN: 1471-2288